Connect with us

Hi, what are you looking for?

News

NewAmsterdam Pharma’s Pioneering Pulse On Alzheimer’s Breakthroughs (NASDAQ:NAMS)

Reason for the update: New clinical data readout

The most recent clinical data from NewAmsterdam Pharma (NASDAQ:NAMS) has showcased the potential of obicetrapib in treating early Alzheimer’s disease (AD), specifically in patients with the apolipoprotein E4 mutation (ApoE4). Buildingtheory

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...

News

This article was written by Follow Andrew Hecht is a 35-year Wall Street veteran covering commodities and precious metals. He runs the investing group...

Videos

Watch full video on YouTube